Wire · opportunities
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 October 2026 · Fusion42 review
The Haystack MRD® test, an ultrasensitive ctDNA liquid biopsy, demonstrated high accuracy and clinical performance in detecting residual and recurrent colorectal cancer, outperforming standard biomarkers in a study involving specimens from the DYNAMIC trials. The study also validated its analytical performance across 23 solid tumor types, confirming its potential to guide treatment decisions and monitor tumor burden changes.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 1 Oct 2026 and 5 Oct 2026.
◆ ◆ The Wire takeaway
You can now offer real-world clinicians a ctDNA test that reliably tracks colorectal cancer recurrence and tumour changes, turning a research tool into a vital clinical asset you can deploy. This creates a clear opening to build treatment monitoring products that improve patient outcomes.
◆ Coverage
2 sources · first reported 1 Oct 2026 · latest 5 Oct 2026
◆ Related on Wire
◆ Topics